Cannabinoid system and neuroinflammation: Implications for multiple sclerosis

NeuroImmunoModulation

Volumn 14, Issue 3-4, 2007, Pages 182-187

  Correa, Fernando ^a   Docagne, Fabian ^a   Mestre, Leyre ^a   Loría, Frida ^a   Hernangómez, Miriam ^a   Borrell, José ^a   Guaza, Carmen ^a  

^a INSTITUTO CAJAL   (Spain)

Author keywords

Cannabinoids; IL 12; Immune function; Microglia; Neuroinflammation; Theiler's virus

Indexed keywords

1 DEOXY 3 (1,1 DIMETHYLBUTYL) DELTA8 TETRAHYDROCANNABINOL; ANANDAMIDE; CANNABINOID; CANNABINOID 2 RECEPTOR; DRONABINOL; GAMMA INTERFERON; IMMUNOMODULATING AGENT; INTERLEUKIN 12; INTERLEUKIN 12P40; INTERLEUKIN 23; LIPOPOLYSACCHARIDE; MESSENGER RNA;

BRAIN; BRAIN FUNCTION; CELL CULTURE; CONFERENCE PAPER; CYTOKINE PRODUCTION; DRUG EFFECT; DRUG MECHANISM; ENCEPHALITIS; ENZYME LINKED IMMUNOSORBENT ASSAY; GLIA CELL; IMMUNE SYSTEM; MACROPHAGE; MICROGLIA; MODULATION; MULTIPLE SCLEROSIS; MURINE ENCEPHALOMYELITIS VIRUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN FAMILY; REGULATORY MECHANISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; BRAIN; CANNABINOIDS; ENCEPHALITIS; ENDOCANNABINOIDS; HUMANS; INTERLEUKIN-12; MULTIPLE SCLEROSIS; RECEPTORS, CANNABINOID; TH1 CELLS;

EID: 37049022168     PISSN: 10217401     EISSN: None     Source Type: Journal    
DOI: 10.1159/000110644     Document Type: Conference Paper

References (44)

1. Gaoni Y, Mechoulam R: Isolation, structure and partial synthesis of an active constituent of hashish. J Am Chem Soc 1964;86:1646-1647.
2. Matsuda LA, Lolait SJ, Brownstein MJ, Young, AC, Bonner TI: Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990;346:561-564.
3. Munro S, Thomas KL, Abu-Shaar M: Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993;365:61-65.
4. Di Marzo V, Breivogel CS, Tao Q, Bridgen DT, Razdan RK, Zimmer AM, Zimmer A, Martin BR: Levels, metabolism and pharmacological activity of anandamide in CB1, cannabinoid receptor knock-out mice: evidence for non CB1, nor CB2 receptor mediated actions of anandamide in mouse brain. J Neurochem 2000;75:2434-2444.
5. Offértaler L, Mo F, Bátkai S, Liu J, Begg M, Razdan RK, Martín BR, Bukoski RD, Kunos F: Selective ligands and cellular effectors of a G protein-coupled endothelial cannabinoid receptor. Mol Pharmacol 2003;63:699-705.
6. Lambert MD, Fowler CJ: The endocannabinoid system: drug targets, lead compounds, and potential therapeutic applications. J Med Chem 2005;48:5059-5087.
7. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, Gibson D, Mandelbaum A, Etinger A, Mechoulam R: Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992;258:1946-1949.
8. Mechoulam R, Ben-Shabat S, Hanus L, Ligumsky M, Kaminski NE, Schatz AR, Gopher A, Almog S, Martin BR, Compton DR: Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 1995;50:83-90.
9. Sugiura T, Kondo S, Sukagawa A, Nakane S, Shinoda A, Itoh K, Yamashita A, Waku K: Arachidonoylglycerol: a possible endogenous cannabinoid recptor ligand in brain. Biochem Biophys Res Commun 1995;215:89-97.
10. Di Marzo V, Fontana A, Cadas H, Schinelli S, Cimino G, Schwartz JC, Piomelli D: Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature 1994;372:689-691.
11. Cravatt BF, Giang DK, Mayfield SP, Boger DL, Lerner RA, Gilula NB: Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature 1996;384:83-87.
12. Galiegue S, Mary S, Marchand J, Dussossoy D, Carriere D, Carayon P, Bouaboula M: Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem 1995;232:54-61.
13. Carlisle SJ, Marciano-Cabral F, Staab A, Ludwick C, Cabral GA: Differential expression of the CB2 cannabinoid receptor by rodent macrophages and macrophage-like cells in relation to cell activation. Int Immunopharmacol 2002;2:69-82.
14. Klein TW: Cannabinoid based drugs as antiinflammatory therapeutics. Nat Rev Immunol 2005;5:400-411.
15. Faubert BL, Rockwell CE, Kaminski NE: Evidence for cannabinoid receptor-dependent and -independent mechanisms of action in leukocytes. J Pharmacol Exp Ther 2003;306:1077-1085.
16. Carayon P, Marchand J, Dussossoy D, Derocq JM, Jbilo O, Bord A, Bouaboula M, Galiegue S, Mondiere P, Penarier G, Fur GL, Defrance T, Casellas P: Modulation and functional involvement of CB2 peripheral receptors during B cell differentiation. Blood 1998;92:3605-3615.
17. McCoy KL, Matmeyeva M, Carlisle SJ, Cabral GA: Cannabinoid inhibition of the processing of intact lysozyme by macrophages: evidence for CB2 receptor participation. J Pharmacol Exp Ther 1999;289:1620-1625.
18. Derocq JM, Jbilo O, Bouaboula M, Segui M, Clere C, Casellas P: Genomic and functional changes induced by the activation of the peripheral cannabinoid receptor CB2 in the promyelocytic cells HL-60: possible involvement of the CB2 receptor in cell differentiation. J Biol Chem 2000;275:15621-15628.
19. Varga K, Wagner JA, Bridgen DT, Kunos G: Platelet and macrophage-derived endogenous cannabinoids are involved in endotoxin-induced hypotension. FASEB J 1998;12:1035-1044.
20. Matias I, Pochard P, Orlando P, Salzet M, Pestel J, Di Marzo V: Presence and regulation of the endocannabinoid system in human dendritic cells. Eur J Biochem 2002;269:3771-3778.
21. 9-tetrahydrocannabinol-induced stimulation of glucose metabolism in primary astrocytes. Mol Pharmacol 1998;54:834-843.
22. Molina-Holgado F, Molina-Holgado E, Guaza C, Rothwell NJ: Role of CB1 and CB2 receptors in the inhibitory effects of cannabinoids on lipopolysaccharide induced nitric oxide release in astrocyte cultures. J Neurosci Res 2002;67:829-836.
23. Facchinetti F, Del Giudice E, Furegato S, Passarotto M, Leon A: Cannabinoids ablate release of TNFα in rat microglial cells stimulated with lypopolysaccharide. Glia 2003;41:161-168.
24. 2 receptor-dependent mechanism. Mol Pharmacol 2004;60:155-163.
25. Walter L, Stella N: Cannabinoids and neuroinflammation. Br J Pharmacol 2004;141:775-785.
26. Molina-Holgado E, Arévalo-Martín A, Vela JM, Almazán G, Molina-Holgado F, Borrell J, Guaza C: Cannabinoids promote oligodendrocyte progenitor survival: Involvement of cannabinoid receptors and phosphatidylinositol-3 kinase/Akt signaling. J Neurosci 2002;22:9742-9753.
27. Romero J, Hillard CJ, Calero M, Rabano A: Fatty acid amide hydrolase localization in the human central nervous system: an immunohistochemical study. Brain Res Mol Brain Res 2002;100:85-93.
28. 9-Tetrahydrocannabinol regulates Th1/Th2 cytokine balance in activated human T cells. J Neuroimmunol 2002;133:124-131.
29. Molina-Holgado F, Molina-Holgado E, Guaza C: The endogenous cannabinoid anandamide potentiates IL-6 production by astrocytes infected with Theiler's murine encephalomyelitis virus by a receptor-mediated pathway. FEBS Lett 1998;433:139-142.
30. Molina-Holgado F, LledóA, Guaza C: Anandamide suppresses nitric oxide and TNF-α responses to Theiler's virus or endotoxin in astrocytes. Neuroreport 1997;8:1929-1933.
31. Puffenbarger RA, Boothe AC, Cabral GA: Cannabinoids inhibit LPS-inducible cytokine mRNA expression in rat microglial cells. Glia 2000;29:58-69.
32. Molina-Holgado F, Pinteaux E, Moore J, Molina-Holgado E, Guaza C, Gibson RM, Rothwell N: Endogenous interleukin-1 receptor antagonist mediates anti-inflammatory and neuroprotective actions of cannabinoids in neurons and glial cells. J Neurosci 2003;23:6470-6474.
33. Trinchieri G: Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 2003;3:133-146.
34. Li J, Gran B, Zhang GX, Ventura ES, Siglienti I, Rostami A, Kamoun M: Differential expression and regulation of IL-23 and IL-12 subunits and receptors in adult mouse microglia. J Neurol Sci 2003;215:95-103.
35. Baker D, Pryce G, Croxford JL, Brown P, Pertwee RG, Huffman JW, Layward L: Cannabinoids control spasticity and tremor in a multiple sclerosis model. Nature 2000;404:84-87.
36. Arévalo-Martin A, Vela JM, Molina-Holgado E, Borrell J, Guaza C: Therapeutic action of cannabinoids in a murine model of multiple sclerosis . J Neurosci 2003;23:2511-2516.
37. +WIN55,212. J Clin Invest 2003;111:1231-1240.
38. Mestre L, Correa F, Arévalo-Martin A, Molina-Holgado E, Valenti M, Ortar G, Di Marzo V, Guaza C: Pharmacological modulation of the endocannabinoid system in a viral model of multiple sclerosis. J Neurochem 2005;92:1327-1339.
39. Ortega-Gutiérrez S, Molina-Holgado E, Arévalo-Martin A, Correa F, Viso A, López-Rodriguez ML, Di Marzo V, Guaza C: Activation of the endocannabinoid system as therapeutic approach in a murine model of multiple sclerosis. FASEB J 2005;19:1338-1340.
40. Eljaschewitsch E, Witting A, Mawrin C, Lee T, Schmidt PM, Wolf S, Hoertnagl H, Raine CS, Schneider-Stock R, Nitsch R, Ullrich O: The endocannabinoid anandamide protects neurons during CNS inflammation by induction of MKP-1 in microglial cells. Neuron 2006;49:67-79.
41. 2 receptors and fatty acid amide hydrolase are specific markers of plaque cell subtypes in human multiple sclerosis. J Neurosci 2007;27:23396-23402.
42. Pryce G, Baker D: Emerging properties of cannabinoid medicines in management of multiple sclerosis. Trends Neurosci 2005;28:272-276.
43. Zajicek J, Fox P, Sanders H, Wright D, Vickery J, Nunn A, Thomson A;UK MS Research Group: Cannabinoids for treatment of spasticity and other symptoms related on multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet 2003;362:1517-1526.
44. Zajicek J, Sansers HP, Wright DE, Vickery PJ, Ingram WM, Reilly SM, Nunn AJ, Teare LJ, Fox PJ, Thompson AJ: Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up. J Neurol Neurosurg Psychiatry 2005;76:1664-1669.